Dagnew AF, Ilhan A, Lee W-S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised clinical trials and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988–1000—In this Article, in page 997, the final paragraph of the results section should have stated “…excluding non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia stratum (two [1·4%] of 148 vaccine group participants and one [0·8%] of 130 placebo group participants; per-protocol cohort for humoral immunogenicity, month 2).” This correction has been made to the online version as of Dec 3, 2019.

中文翻译：

---

更正《柳叶刀感染病》 2019; 19：988-1000。

Dagnew AF，Ilhan A，Lee WS等。成人血液系统恶性肿瘤佐剂重组带状疱疹疫苗的免疫原性和安全性：第3阶段，随机临床试验和事后功效分析。《柳叶刀》杂志Infect Dis 2019; 19：988–1000 —在本文的第997页中，结果部分的最后一段应说明：“……不包括非霍奇金B细胞淋巴瘤和慢性淋巴细胞性白血病层（148种疫苗中有两种[1·4％]组参与者和130个安慰剂组参与者中的1个[0·8％]；针对体液免疫原性的每个协议队列，第2个月）。” 自2019年12月3日起对在线版本进行了更正。